Psychemedics Corporation (PMD)

Market Cap	32.29M
Revenue (ttm)	25.97M
Net Income (ttm)	-2.02M
Shares Out	5.63M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	$0.26 (4.53%)
Ex-Dividend Date	Dec 1, 2022

Volume	3,455
Open	5.76
Previous Close	5.72
Day's Range	5.72 - 5.76
52-Week Range	5.61 - 8
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2022

About PMD

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium...

• Industry: Health Care Providers & Services
• Founded: 1986
• Employees: 139
• Stock Exchange: NASDAQ
• Ticker Symbol: PMD

Financial Performance

In 2021, Psychemedics's revenue was $24.91 million, an increase of 16.62% compared to the previous year's $21.36 million. Losses were -$665,000, -82.77% less than in 2020.